CHURCHILL MANAGEMENT Corp Has $18.79 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

CHURCHILL MANAGEMENT Corp lessened its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 1.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 366,695 shares of the biopharmaceutical company’s stock after selling 3,707 shares during the quarter. Pfizer comprises approximately 0.4% of CHURCHILL MANAGEMENT Corp’s portfolio, making the stock its 24th largest holding. CHURCHILL MANAGEMENT Corp’s holdings in Pfizer were worth $18,789,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of PFE. RB Capital Management LLC raised its position in Pfizer by 6.7% in the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 341 shares during the last quarter. Ironwood Wealth Management LLC. grew its stake in Pfizer by 1.1% in the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after purchasing an additional 400 shares in the last quarter. United Bank grew its stake in Pfizer by 0.6% in the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after purchasing an additional 290 shares in the last quarter. Ergoteles LLC grew its stake in Pfizer by 136.3% in the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after purchasing an additional 21,209 shares in the last quarter. Finally, Mackenzie Financial Corp grew its stake in Pfizer by 6.4% in the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after purchasing an additional 79,887 shares in the last quarter. Institutional investors and hedge funds own 67.62% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the subject of a number of analyst reports. JPMorgan Chase & Co. set a $45.00 price target on Pfizer in a research note on Monday, February 27th. Jefferies Financial Group initiated coverage on Pfizer in a research note on Monday, March 6th. They issued a “hold” rating and a $43.00 price target for the company. Wells Fargo & Company decreased their price target on Pfizer from $50.00 to $44.00 and set an “equal weight” rating for the company in a research note on Friday. Atlantic Securities reduced their target price on Pfizer from $50.00 to $46.00 and set a “neutral” rating for the company in a research note on Wednesday, February 1st. Finally, BMO Capital Markets reduced their target price on Pfizer from $55.00 to $53.00 and set an “outperform” rating for the company in a research note on Wednesday, February 1st. Nine analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average target price of $50.38.

Pfizer Stock Performance

PFE opened at $40.10 on Friday. The company has a market capitalization of $225.33 billion, a PE ratio of 7.32, a price-to-earnings-growth ratio of 1.33 and a beta of 0.64. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.22 and a quick ratio of 1.00. The business has a fifty day simple moving average of $43.26 and a 200 day simple moving average of $46.03. Pfizer Inc. has a 1 year low of $39.23 and a 1 year high of $56.32.

Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings data on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.11. The firm had revenue of $24.30 billion during the quarter, compared to analysts’ expectations of $24.40 billion. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.08 EPS. Research analysts expect that Pfizer Inc. will post 3.33 EPS for the current year.

About Pfizer

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.